Syndexa Garners Series B Round

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    480 Arsenal Street Building 1 Watertown, MA 02472
  • Company Description
    The company develops drugs targeting novel biological mechanisms for the treatment and prevention of metabolic diseases including obesity, type 2 diabetes and cardiovascular disease.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series B
  • Proceeds Purposes
    The proceeds from our Series B1 will enable us to progress the preclinical development of our Endoplasmic Reticulum (ER) modulating compounds towards development candidate selection, and will allow us to validate the therapeutic potential of our most promising compounds in various indications of ER dysfunction.
  • M&A Terms
  • Venture Investor
    MP Healthcare Venture Management

Trending on Xconomy